NASDAQ:BVS - Nasdaq - US09075A1088 - Common Stock - Currency: USD
10.01
+0.06 (+0.6%)
The current stock price of BVS is 10.01 USD. In the past month the price increased by 0.4%. In the past year, price increased by 109.41%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ALC | ALCON INC | 29.9 | 45.13B | ||
COO | COOPER COS INC/THE | 23.91 | 17.66B | ||
ALGN | ALIGN TECHNOLOGY INC | 20.39 | 14.22B | ||
SOLV | SOLVENTUM CORP | 17.55 | 12.61B | ||
MMSI | MERIT MEDICAL SYSTEMS INC | 30.7 | 6.01B | ||
BLCO | BAUSCH + LOMB CORP | 25.4 | 5.55B | ||
LNTH | LANTHEUS HOLDINGS INC | 11.27 | 5.44B | ||
ICUI | ICU MEDICAL INC | 27.69 | 3.85B | ||
XRAY | DENTSPLY SIRONA INC | 10.14 | 3.73B | ||
HAE | HAEMONETICS CORP/MASS | 14.9 | 3.17B | ||
NEOG | NEOGEN CORP | 25.1 | 2.18B | ||
UFPT | UFP TECHNOLOGIES INC | 36.31 | 1.95B |
Bioventus, Inc. is a medical technology company, which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. The company is headquartered in Durham, North Carolina and currently employs 1,030 full-time employees. The company went IPO on 2021-02-11. The firm is focused on developing and commercializing clinically differentiated and minimally invasive treatments that engage and enhance the body’s natural healing process. Its portfolio of products is grouped into three areas. Its Pain Treatments include non-surgical pain injection therapies as well as peripheral nerve stimulation (PNS) products to help the patient get back to their normal activities. Its Surgical Solutions include bone graft substitutes (BGS) that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries, as well as a portfolio of ultrasonic products used for precise bone cutting and sculpting, soft tissue management and tissue debridement in various surgeries. Its Restorative Therapies comprise a bone stimulation system, as well as devices designed to help patients regain leg or hand function due to stroke, multiple sclerosis or other central nervous system disorders.
BIOVENTUS INC - A
4721 Emperor Boulevard, Suite 100
Durham NORTH CAROLINA 27703 US
CEO: Kenneth M. Reali
Employees: 1030
Company Website: https://www.bioventus.com/
Investor Relations: https://ir.bioventus.com/stock-information/stock-quote-chart
Phone: 19194746700
The current stock price of BVS is 10.01 USD. The price increased by 0.6% in the last trading session.
The exchange symbol of BIOVENTUS INC - A is BVS and it is listed on the Nasdaq exchange.
BVS stock is listed on the Nasdaq exchange.
7 analysts have analysed BVS and the average price target is 15.3 USD. This implies a price increase of 52.85% is expected in the next year compared to the current price of 10.01. Check the BIOVENTUS INC - A stock analysts ratings, price target forecast and up-and down grades for more detailed information.
BIOVENTUS INC - A (BVS) has a market capitalization of 812.31M USD. This makes BVS a Small Cap stock.
BIOVENTUS INC - A (BVS) currently has 1030 employees.
BIOVENTUS INC - A (BVS) has a support level at 9.5 and a resistance level at 10.03. Check the full technical report for a detailed analysis of BVS support and resistance levels.
The Revenue of BIOVENTUS INC - A (BVS) is expected to grow by 12.78% in the next year. Check the estimates tab for more information on the BVS EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
BVS does not pay a dividend.
BIOVENTUS INC - A (BVS) will report earnings on 2025-03-10, after the market close.
The PE ratio for BIOVENTUS INC - A (BVS) is 25.67. This is based on the reported non-GAAP earnings per share of 0.39 and the current share price of 10.01 USD. Check the full fundamental report for a full analysis of the valuation metrics for BVS.
The outstanding short interest for BIOVENTUS INC - A (BVS) is 1.41% of its float. Check the ownership tab for more information on the BVS short interest.
ChartMill assigns a technical rating of 5 / 10 to BVS. When comparing the yearly performance of all stocks, BVS is one of the better performing stocks in the market, outperforming 93.96% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to BVS. There are concerns on the financial health of BVS while its profitability can be described as average.
Over the last trailing twelve months BVS reported a non-GAAP Earnings per Share(EPS) of 0.39. The EPS increased by 400% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -5.13% | ||
ROE | -26.54% | ||
Debt/Equity | 2.32 |
ChartMill assigns a Buy % Consensus number of 77% to BVS. The Buy consensus is the average rating of analysts ratings from 7 analysts.